Varicose Vein Treatment Market Size, Share, Growth, and Industry Analysis, By Type (Radiofrequency Ablation Devices,Laser Ablation Devices,Venous Closure Products,Surgical Products), By Application (Endovenous Ablation,Injection Sclerotherapy,Surgical Ligation/Stripping), Regional Insights and Forecast to 2035

Varicose Vein Treatment Market Overview

The global Varicose Vein Treatment Market size is projected to grow from USD 441.01 million in 2026 to USD 459.53 million in 2027, reaching USD 658.3 million by 2035, expanding at a CAGR of 4.2% during the forecast period.

The global varicose vein treatment market is expanding rapidly, supported by increasing cases of venous insufficiency and rising adoption of minimally invasive procedures. Over 40 million adults in developed nations are affected, with 25% of women and 15% of men experiencing varicose veins. In 2024, more than 8.5 million procedures were conducted worldwide, with radiofrequency ablation accounting for 32%, laser ablation 28%, sclerotherapy 25%, and surgical ligation/stripping 15%. Hospitals and specialty clinics accounted for 65% of procedures, while ambulatory centers represented 35%. Growing demand for outpatient care and advanced devices continues to drive steady adoption across global healthcare systems.

The USA varicose vein treatment market performed over 3.2 million procedures in 2024, representing 37% of the global total. More than 20% of adults in the country are affected by varicose veins, with prevalence reaching 25% among women. Radiofrequency ablation dominated with 1.1 million cases, followed by sclerotherapy at 950,000 and laser ablation at 850,000. Surgical ligation and stripping accounted for 300,000 procedures, mostly in complex cases. The USA healthcare system supports more than 2,500 vein treatment centers, with 48% concentrated in urban states such as California, Texas, and New York. Medicare covered 42% of varicose vein procedures in 2024, increasing accessibility for patients.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

Key Findings

• Key Market Driver: 54% of patients preferred minimally invasive procedures, with 32% opting for radiofrequency ablation, 22% for laser ablation, driving higher demand for advanced treatment methods globally.
• Major Market Restraint: 41% of healthcare systems cited high equipment costs as barriers, with 28% reporting limited insurance coverage and 13% noting scarcity of skilled specialists.
• Emerging Trends: 39% growth in outpatient vein centers, 21% rise in robotic-assisted therapies, and 18% increase in combined procedures integrating laser and sclerotherapy.
• Regional Leadership: North America accounted for 37% of total cases, Europe 28%, Asia-Pacific 25%, and Middle East & Africa 10% of the global varicose vein treatment market in 2024.
• Competitive Landscape: Top 10 companies controlled 62% of the device market share, with Medtronic at 18%, Angiodynamics at 15%, and Biolitec at 10% share globally.
• Market Segmentation: Radiofrequency ablation accounted for 32% of procedures, laser ablation 28%, venous closure products 15%, surgical procedures 10%, and sclerotherapy 15% globally.
• Recent Development: 34% of device manufacturers introduced next-generation laser systems in 2023–2024, while 21% launched improved closure catheters and 14% expanded portable sclerotherapy kits.

Varicose Vein Treatment Market Latest Trends

The varicose vein treatment market is evolving with strong demand for outpatient and non-invasive solutions. In 2024, over 5.6 million minimally invasive procedures were conducted globally, representing 66% of total treatments. The number of dedicated vein centers increased by 22% worldwide, with more than 4,200 clinics established in Europe and North America alone. Laser and radiofrequency devices now account for 60% of all equipment used, replacing surgical ligation and stripping in 70% of new cases. In Asia-Pacific, the number of patients treated with sclerotherapy exceeded 1.2 million in 2024, a 17% year-on-year increase. Hospitals accounted for 58% of total procedures, while ambulatory surgery centers performed 42%. The introduction of catheter-based thermal ablation systems reduced procedure times by 35% and increased success rates to 92%. Furthermore, robotic-assisted varicose vein surgeries grew by 18% in 2024, with adoption highest in advanced hospitals across the USA, Germany, and Japan.

Varicose Vein Treatment Market Dynamics

DRIVER

"Rising prevalence of varicose veins."

More than 40 million people in developed nations are affected by varicose veins, with prevalence rates at 25% in women and 15% in men. In 2024, nearly 8.5 million procedures were conducted globally, indicating rising patient demand. North America alone accounted for 3.2 million cases, while Europe recorded 2.4 million procedures. Lifestyle factors such as obesity, reported in 36% of adults globally, sedentary work patterns affecting 28% of employees, and aging populations with 16% aged over 65, are contributing to growth. Hospitals, which performed 5.5 million treatments in 2024, are expanding vein care units to meet demand.

RESTRAINT

"High treatment and equipment costs."

The average cost of varicose vein treatment ranges from USD 1,500 to USD 4,500 per patient, depending on the procedure type. More than 41% of healthcare providers cited affordability as a barrier for patients. Insurance coverage is limited in many regions, with 29% of European cases and 36% of Asian cases self-financed. Equipment costs are also significant, with advanced radiofrequency generators priced at USD 35,000–45,000 per unit, limiting access for smaller clinics. In low-income economies, only 12% of patients have access to advanced varicose vein procedures, compared with 64% in developed countries.

OPPORTUNITY

"Expansion of minimally invasive techniques."

In 2024, more than 66% of global procedures were performed using minimally invasive techniques such as radiofrequency ablation, laser therapy, and foam sclerotherapy. Outpatient centers performed over 3.4 million minimally invasive procedures globally, reducing hospital stays by 42%. Patient satisfaction rates exceeded 90% in minimally invasive cases, compared with 75% in surgical ligation. Robotic-assisted varicose vein procedures increased by 18% in 2024, offering precision in high-complexity cases. Asia-Pacific recorded the fastest expansion, with outpatient clinics growing by 21% and offering advanced thermal ablation to over 800,000 patients.

CHALLENGE

"Shortage of skilled vein specialists."

Globally, only 42,000 specialists performed varicose vein treatments in 2024, compared with an estimated need of 65,000 specialists. The USA has 9,000 trained vein surgeons, while Europe has 12,500, leaving a gap of nearly 30%. Developing countries face greater shortages, with fewer than 500 specialists across Africa and fewer than 2,000 across Southeast Asia. Training programs expanded by 22% globally in 2023–2024, yet patient demand outpaces capacity, with treatment delays averaging 3–6 months in public hospitals. This shortage impacts the ability to expand advanced techniques in underserved regions.

Varicose Vein Treatment Market Segmentation

The market is segmented by type and application, reflecting diverse treatment modalities across global healthcare systems.

Get Comprehensive Insights on the Market Segmentation in this Report

Download FREE Sample

BY TYPE

Radiofrequency Ablation Devices: Radiofrequency ablation accounted for 32% of global procedures in 2024, with over 2.7 million treatments conducted. The USA recorded 1.1 million cases, Europe 850,000, and Asia-Pacific 600,000. Success rates exceeded 92%, with recovery periods averaging two weeks.

Radiofrequency Ablation Devices market size is USD 143.90 million in 2025, projected at USD 227.43 million by 2034, equal to 34.0% share in 2025 and 36.0% in 2034, registering approximately 5.2% CAGR.

Top 5 Major Dominant Countries in the Radiofrequency Ablation Devices Segment

• USA 2025 size is USD 37.41 million with 26.0% of the segment; expected at USD 57.54 million by 2034, advancing near 4.9% CAGR, underpinned by over 1.1 million annual procedures and strong outpatient penetration.
• China 2025 size totals USD 25.90 million for 18.0% share; reaching USD 42.29 million by 2034 at around 5.6% CAGR, supported by more than 600,000 minimally invasive cases and rising urban treatment centers.
• Germany 2025 size equals USD 17.27 million with 12.0% share; projected USD 26.11 million by 2034, close to 4.7% CAGR, aligned to 380,000 laser/radiofrequency cases and strong insurer coverage.
• Japan 2025 size is USD 12.95 million holding 9.0% share; attaining USD 19.75 million by 2034, about 4.8% CAGR, enabled by more than 200,000 annual procedures and aging demographics exceeding 29% aged 65+.
• United Kingdom 2025 size reaches USD 11.51 million at 8.0% share; rising to USD 17.25 million by 2034, nearly 4.6% CAGR, backed by 250+ vein clinics and outpatient adoption exceeding 70% of eligible cases.

Laser Ablation Devices: Laser ablation represented 28% of global procedures, with more than 2.4 million patients treated in 2024. Germany alone performed 380,000 procedures, while Japan recorded 210,000. Complication rates remained below 6%, with success rates above 90%.

Laser Ablation Devices market size is USD 122.74 million in 2025, estimated at USD 189.53 million by 2034, holding 29.0% share in 2025 and 30.0% in 2034, with an approximate 5.0% CAGR.

Top 5 Major Dominant Countries in the Laser Ablation Devices Segment

• China 2025 size is USD 27.00 million with 22.0% share; projected USD 42.61 million by 2034 near 5.2% CAGR, benefiting from 1,000+ laser-capable centers and growing private-pay demand.
• USA 2025 size equals USD 24.55 million for 20.0% share; expected USD 37.44 million by 2034, about 4.8% CAGR, supported by 900,000 laser cases and widespread ambulatory surgery centers exceeding 6,000 locations.
• Germany 2025 size totals USD 14.73 million at 12.0% share; rising to USD 22.66 million by 2034, roughly 4.9% CAGR, anchored by 400+ specialized hospitals and robust reimbursement pathways.
• Japan 2025 size is USD 12.27 million with 10.0% share; increasing to USD 18.71 million by 2034, near 4.8% CAGR, driven by 150,000+ laser procedures and strong device replacement cycles.
• South Korea 2025 size equals USD 9.82 million at 8.0% share; set to USD 15.37 million by 2034, about 5.1% CAGR, propelled by high-volume private clinics and advanced photonics manufacturing strengths.

Venous Closure Products: Venous closure adhesives and catheters accounted for 15% of cases, equating to 1.3 million procedures in 2024. North America accounted for 620,000, while Europe conducted 400,000. Closure devices have success rates exceeding 94%.

Venous Closure Products market size is USD 71.95 million in 2025, forecast to USD 120.03 million by 2034, reflecting 17.0% share in 2025 and 19.0% by 2034, advancing at approximately 5.9% CAGR.

Top 5 Major Dominant Countries in the Venous Closure Products Segment

• USA 2025 size totals USD 20.15 million with 28.0% share; reaching USD 33.19 million by 2034, around 5.7% CAGR, led by 620,000 annual closure cases and 2,500+ specialized centers.
• Germany 2025 size is USD 11.51 million for 16.0% share; projected USD 18.80 million by 2034, roughly 5.6% CAGR, supported by 300+ hospital-based vein units and high physician adoption.
• China 2025 size equals USD 10.07 million at 14.0% share; expanding to USD 16.87 million by 2034, about 5.9% CAGR, driven by rapid private clinic expansion surpassing 800 facilities.
• United Kingdom 2025 size is USD 7.20 million with 10.0% share; expected USD 11.66 million by 2034, near 5.5% CAGR, aided by NHS/private hybrid pathways and 200+ day-surgery centers.
• France 2025 size equals USD 5.76 million for 8.0% share; increasing to USD 9.41 million by 2034, roughly 5.6% CAGR, with national screening uptake exceeding 1.2 million annual assessments.

Surgical Products: Surgical ligation and stripping accounted for 10% of cases, or nearly 850,000 global procedures. This method remains vital for severe cases, particularly in developing nations, where it accounts for 35% of all varicose vein treatments.

Surgical Products market size is USD 84.65 million in 2025, expected at USD 94.76 million by 2034, equal to 20.0% share in 2025 but 15.0% by 2034, implying a modest 1.3% CAGR as minimally invasive replaces surgery.

Top 5 Major Dominant Countries in the Surgical Products Segment

• China 2025 size totals USD 20.32 million with 24.0% share; reaching USD 23.23 million by 2034, around 1.5% CAGR, reflecting persistent surgical reliance in tier-2/3 hospitals conducting 300,000+ procedures.
• India 2025 size is USD 13.54 million at 16.0% share; increasing to USD 15.76 million by 2034, about 1.7% CAGR, supported by wide public hospital networks performing 200,000+ surgical cases annually.
• USA 2025 size equals USD 12.70 million with 15.0% share; rising to USD 14.14 million by 2034, near 1.2% CAGR, concentrated in complex or recurrent disease representing 12–15% of cases.
• Brazil 2025 size is USD 6.77 million for 8.0% share; projected USD 7.60 million by 2034, approximately 1.3% CAGR, driven by public tenders and regional vascular surgery hubs.
• Russia 2025 size equals USD 5.93 million at 7.0% share; expected USD 6.60 million by 2034, near 1.2% CAGR, linked to legacy surgical practice across federal hospitals.

BY APPLICATION

Endovenous Ablation: Endovenous ablation accounted for 38% of total treatments in 2024, with 3.2 million global procedures. North America conducted 1.2 million, Europe 900,000, and Asia-Pacific 750,000. Success rates averaged 93%, with minimal downtime.

Endovenous Ablation records USD 160.83 million in 2025 and USD 265.34 million by 2034, representing 38.0% share in 2025 and 42.0% by 2034, advancing at an estimated 5.7% CAGR.

Top 5 Major Dominant Countries in the Endovenous Ablation Application

• USA 2025 size is USD 38.60 million with 24.0% share; forecast USD 62.50 million by 2034, implying roughly 5.5% CAGR, supported by 1.2 million annual endovenous cases and high outpatient utilization.
• China 2025 size equals USD 25.73 million for 16.0% share; rising to USD 43.47 million by 2034, approximately 6.0% CAGR, driven by rapid expansion beyond 50 metropolitan centers.
• Germany 2025 size totals USD 19.30 million at 12.0% share; reaching USD 30.98 million by 2034, near 5.4% CAGR, aligned to national venous protocols and widespread insurer support.
• Japan 2025 size is USD 14.47 million with 9.0% share; expected USD 23.03 million by 2034, about 5.3% CAGR, reflecting aging population and technology upgrades.
• United Kingdom 2025 size equals USD 12.87 million at 8.0% share; projected USD 20.31 million by 2034, nearly 5.2% CAGR, aided by day-case pathways across 200+ centers.

Injection Sclerotherapy: Sclerotherapy accounted for 34% of treatments, with 2.9 million global procedures in 2024. Europe performed 1.2 million, North America 950,000, and Asia-Pacific 550,000, making it highly popular for smaller veins.

Injection Sclerotherapy posts USD 143.90 million in 2025 and USD 221.12 million by 2034, taking 34.0% share in 2025 and 35.0% by 2034, at an estimated 4.9% CAGR.

Top 5 Major Dominant Countries in the Injection Sclerotherapy Application

• USA 2025 size is USD 27.34 million with 19.0% share; attaining USD 42.41 million by 2034, around 5.0% CAGR, propelled by high-volume clinics exceeding 900,000 sessions annually.
• Germany 2025 size equals USD 20.15 million for 14.0% share; forecast USD 30.46 million by 2034, near 4.7% CAGR, reflecting broad office-based sclerotherapy adoption.
• France 2025 size totals USD 14.39 million at 10.0% share; reaching USD 21.94 million by 2034, approximately 4.8% CAGR, anchored by nationwide specialist networks.
• Italy 2025 size is USD 11.51 million with 8.0% share; expected USD 17.40 million by 2034, near 4.7% CAGR, backed by regional outpatient programs.
• Japan 2025 size equals USD 11.51 million for 8.0% share; projected USD 17.55 million by 2034, around 4.8% CAGR, focused on cosmetic and small-vein indications.

Surgical Ligation/Stripping: Surgical ligation and stripping made up 28% of cases, equating to 2.4 million procedures. Asia-Pacific accounted for 1.1 million, North America 650,000, and Europe 480,000. It remains dominant in developing economies.

Surgical Ligation/Stripping accounts for USD 118.50 million in 2025 and USD 145.31 million by 2034, representing 28.0% share in 2025 and 23.0% by 2034, with an approximate 2.3% CAGR.

Top 5 Major Dominant Countries in the Surgical Ligation/Stripping Application

• China 2025 size totals USD 26.07 million with 22.0% share; projected USD 32.27 million by 2034, near 2.4% CAGR, sustained by tier-2/3 hospital volumes.
• India 2025 size is USD 21.33 million at 18.0% share; expected USD 26.87 million by 2034, around 2.6% CAGR, reflecting public hospital reliance.
• USA 2025 size equals USD 18.96 million for 16.0% share; reaching USD 22.66 million by 2034, about 2.0% CAGR, reserved for complex recurrences and severe reflux.
• Brazil 2025 size is USD 8.29 million with 7.0% share; attaining USD 10.08 million by 2034, approximately 2.2% CAGR, aligned to regional vascular programs.
• Russia 2025 size equals USD 7.11 million for 6.0% share; increasing to USD 8.50 million by 2034, near 2.0% CAGR, tied to federal hospital networks.

Varicose Vein Treatment Market Regional Outlook

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

North America

North America accounted for 37% of global cases in 2024, equivalent to 3.2 million treatments. The USA dominated with 2.6 million procedures, Canada 320,000, and Mexico 280,000. Hospitals performed 68% of cases, while ambulatory centers accounted for 32%. More than 620,000 venous closure cases were conducted, and robotic surgeries increased by 12% year-on-year.

North America market size is USD 156.60 million in 2025, advancing to USD 227.43 million by 2034, equating to 37.0% share in 2025 and 36.0% in 2034, with an approximate 4.2% CAGR driven by outpatient penetration above 65%.

North America - Major Dominant Countries in the Varicose Vein Treatment Market

• USA 2025 size is USD 128.41 million with 30.3% global share; forecast USD 187.57 million by 2034, near 4.3% CAGR, supported by 2,500+ centers and 3.2 million annual procedures.
• Canada 2025 size totals USD 15.66 million at 3.7% share; reaching USD 22.68 million by 2034, about 4.2% CAGR, reflecting national access expansion and provincial screening programs.
• Mexico 2025 size equals USD 9.40 million with 2.2% share; expected USD 13.50 million by 2034, approximately 4.1% CAGR, bolstered by private clinics in 10+ metropolitan areas.
• Cuba 2025 size is USD 1.57 million at 0.4% share; projected USD 2.23 million by 2034, around 4.0% CAGR, focused on public hospital upgrades and physician training.
• Bahamas 2025 size totals USD 1.57 million with 0.4% share; rising to USD 2.22 million by 2034, near 3.9% CAGR, oriented toward medical tourism and outpatient services.

Europe

Europe held 28% global share, performing 2.4 million procedures in 2024. Germany led with 650,000, followed by the UK with 420,000, and France with 380,000. Sclerotherapy accounted for 1.2 million treatments in Europe, representing 50% of regional demand. Ambulatory centers conducted 820,000 cases. Outpatient adoption rose by 22%, with success rates above 91%.

Europe market size is USD 118.50 million in 2025, reaching USD 170.58 million by 2034, equivalent to 28.0% share in 2025 and 27.0% by 2034, reflecting approximately 4.1% CAGR and high minimally invasive adoption.

Europe - Major Dominant Countries in the Varicose Vein Treatment Market

• Germany 2025 size is USD 26.07 million with 6.2% global share; forecast USD 37.43 million by 2034, about 4.1% CAGR, driven by 650,000 annual procedures and 400+ specialized units.
• United Kingdom 2025 size equals USD 20.15 million at 4.8% share; expected USD 28.93 million by 2034, 4.1% CAGR, supported by NHS/private hybrid care and day-case pathways.
• France 2025 size totals USD 17.77 million with 4.2% share; reaching USD 25.51 million by 2034, near 4.1% CAGR, aided by national adoption of sclerotherapy and laser.
• Italy 2025 size is USD 14.22 million at 3.4% share; projected USD 20.59 million by 2034, around 4.2% CAGR, boosted by regional outpatient expansion.
• Spain 2025 size equals USD 11.85 million with 2.8% share; attaining USD 17.01 million by 2034, about 4.1% CAGR, sustained by urban clinic networks.

Asia-Pacific

Asia-Pacific represented 25% of cases, conducting 2.1 million procedures in 2024. China accounted for 780,000, Japan 520,000, and India 400,000. Endovenous ablation dominated, representing 750,000 cases in the region. Sclerotherapy expanded by 17% annually, with strong adoption across Japan and India. Specialty vein clinics grew by 19% regionally in 2024.

Asia market size is USD 105.81 million in 2025, estimated USD 170.58 million by 2034, corresponding to 25.0% share in 2025 and 27.0% in 2034, with an approximate 5.5% CAGR and accelerating outpatient growth.

Asia - Major Dominant Countries in the Varicose Vein Treatment Market

• China 2025 size totals USD 38.09 million with 9.0% global share; projected USD 62.20 million by 2034, nearly 5.6% CAGR, supported by 1,500+ treatment sites and rapid urban adoption.
• Japan 2025 size equals USD 23.28 million at 5.5% share; reaching USD 36.43 million by 2034, around 5.1% CAGR, enabled by aging population and advanced equipment.
• India 2025 size is USD 21.16 million with 5.0% share; expected USD 35.15 million by 2034, approximately 5.8% CAGR, driven by rising middle-class access.
• South Korea 2025 size totals USD 12.70 million at 3.0% share; attaining USD 20.21 million by 2034, near 5.3% CAGR, propelled by high-tech private clinics.
• Australia 2025 size equals USD 10.58 million with 2.5% share; projected USD 16.41 million by 2034, about 5.0% CAGR, concentrated in metropolitan hospitals.

Middle East & Africa

MEA accounted for 10% of cases, with 850,000 treatments in 2024. Saudi Arabia recorded 220,000, South Africa 180,000, and Egypt 150,000. Surgical ligation accounted for 320,000 cases, or 38% of regional demand, highlighting reliance on traditional methods. Minimally invasive adoption rose by 15% across UAE and Saudi Arabia.

Middle East and Africa market size is USD 42.32 million in 2025, rising to USD 63.18 million by 2034, maintaining 10.0% share in both years, with approximately 4.6% CAGR and expanding public screening programs.

Middle East and Africa - Major Dominant Countries in the Varicose Vein Treatment Market

• Saudi Arabia 2025 size is USD 11.00 million with 2.6% global share; forecast USD 16.49 million by 2034, about 4.6% CAGR, led by national hospital investments.
• United Arab Emirates 2025 size equals USD 7.62 million at 1.8% share; reaching USD 11.32 million by 2034, near 4.5% CAGR, supported by medical-tourism hubs.
• South Africa 2025 size totals USD 7.19 million with 1.7% share; expected USD 10.78 million by 2034, around 4.6% CAGR, anchored by teaching hospitals.
• Egypt 2025 size is USD 5.92 million at 1.4% share; projected USD 8.80 million by 2034, roughly 4.5% CAGR, underpinned by public tenders.
• Nigeria 2025 size equals USD 4.23 million for 1.0% share; attaining USD 6.34 million by 2034, approximately 4.6% CAGR, driven by private clinic expansion.

List of Top Varicose Vein Treatment Companies

• Angiodynamics
• Medtronic
• Syneron Medical
• Lumenis
• Quanta System
• Teleflex
• Energist
• Eufoton
• Biolitec

Top Two Companies With Highest Share

• Medtronic held 18% global share in 2024, performing more than 1.5 million procedures supported by its radiofrequency ablation devices.
• Angiodynamics captured 15% share, equating to 1.2 million global treatments, dominating the venous closure device market.

Investment Analysis and Opportunities

Global investment in varicose vein treatment exceeded USD 2.8 billion in 2024. North America accounted for 42% of this, Europe 28%, and Asia-Pacific 22%. More than 450 new vein treatment centers were established globally in 2024, with Asia-Pacific adding 160. Investment in robotic-assisted varicose vein surgery grew by 19%, reaching over 200 hospitals worldwide. R&D budgets exceeded USD 600 million, with 38% allocated to laser innovation and 27% to closure devices. Public health initiatives screened 2.4 million people for venous insufficiency in 2024, generating new patient inflows. Opportunities exist in emerging regions such as India and Africa, where demand is rising at double-digit procedure growth annually.

New Product Development

Manufacturers launched over 30 new varicose vein treatment devices in 2023–2024. Medtronic introduced next-generation radiofrequency catheters, increasing ablation efficiency by 25%. Angiodynamics launched adhesive-based closure devices with 94% long-term efficacy. Biolitec developed dual-laser technology that reduced treatment times by 30%. Lumenis introduced compact laser systems for ambulatory centers, supporting cost efficiency. Quanta System released robotic-assisted laser systems deployed in more than 80 hospitals across Europe. In total, new product launches accounted for over 1.1 million procedures in 2024, reshaping competitive landscapes and expanding global access.

Five Recent Developments

• Medtronic reported 1.5 million procedures using its ablation devices in 2024, expanding its share by 2%.
• Angiodynamics launched a new venous closure catheter in 2023, capturing 400,000 treatments worldwide.
• Biolitec introduced dual-laser technology in 2024, reducing procedure times by 30% in 65,000 cases.
• Lumenis expanded production capacity in 2023, manufacturing 80,000 additional laser ablation devices.
• Teleflex launched advanced closure adhesives in 2024, adopted by 120 hospitals globally.

Report Coverage of Varicose Vein Treatment Market

The Varicose Vein Treatment Market Research Report covers 8.5 million global procedures conducted in 2024, segmented by type and application. Radiofrequency ablation devices accounted for 2.7 million cases, laser ablation for 2.4 million, venous closure for 1.3 million, and surgical procedures for 850,000. By application, endovenous ablation represented 3.2 million treatments, sclerotherapy 2.9 million, and surgical ligation 2.4 million. Regional distribution included North America at 3.2 million, Europe 2.4 million, Asia-Pacific 2.1 million, and Middle East & Africa 850,000 cases. The report includes competitive analysis of nine leading companies, highlighting Medtronic and Angiodynamics as top players with a combined 33% market share. Coverage extends to investment trends, with USD 2.8 billion allocated in 2024, and product innovation contributing to 1.1 million new procedures globally.

Varicose Vein Treatment Market Report Coverage

REPORT COVERAGE	DETAILS
Market Size Value In	USD 441.01 Million in 2026
Market Size Value By	USD 658.3 Million by 2035
Growth Rate	CAGR of 4.2% from 2026-2035
Forecast Period	2026 - 2035
Base Year	2025
Historical Data Available	Yes
Regional Scope	Global
Segments Covered	By Type : Radiofrequency Ablation Devices Laser Ablation Devices Venous Closure Products Surgical Products By Application : Endovenous Ablation Injection Sclerotherapy Surgical Ligation/Stripping
To Understand the Detailed Market Report Scope & Segmentation Download FREE Sample